Lieping Chen

Immunology · 2000–2018

A researcher in the Science corpus: 24 papers; trusts 36 researchers and is trusted by 45 researchers here, as inferred from the citation graph.

Subfields

• Immunology — 367 citations into it; #46 of 2,160 by trust here, #12 by citations
• Oncology — 315 citations into it; #22 of 1,698 by trust here, #20 by citations
• Psychiatry and Mental health — 7 citations into it
• Biomedical Engineering — 5 citations into it

Whom Lieping Chen trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

1. W. Zou
2. D. Pardoll
3. Taku Okazaki
4. Jérôme Galon
5. G. Freeman
6. M. Croft
7. Daniel L. Barber
8. Janis Taube
9. I. Crispe
10. Loise M. Francisco

Who trusts Lieping Chen overall

1. W. Zou
2. Jong-Ho Cha
3. Kole T. Roybal
4. Daniel L. Barber
5. Xue Han
6. Jang-Hwan Cho
7. E. Buchbinder
8. E. Wherry
9. Arlene H. Sharpe
10. Yiping Yang

Papers from Lieping Chen's perspective

Ordered by how strongly the researchers Lieping Chen trusts endorse each paper. Same corpus, a different order for every researcher.

1. Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. (Science)
2. Blockade of B7-H1 improves myeloid dendritic cell–mediated antitumor immunity (Nature Medicine)
3. Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation (Journal of Experimental Medicine)
4. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells (Nature Immunology)
5. Improved Survival with Ipilimumab in Patients with Metastatic Melanoma (New England Journal of Medicine)
6. Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma (Nature Medicine)
7. Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome (Science)
8. The Programmed Death-1 (PD-1) Pathway Regulates Autoimmune Diabetes in Nonobese Diabetic (NOD) Mice (Journal of Experimental Medicine)
9. SHP-1 and SHP-2 Associate with Immunoreceptor Tyrosine-Based Switch Motif of Programmed Death 1 upon Primary Human T Cell Stimulation, but Only Receptor Ligation Prevents T Cell Activation1 (Journal of Immunology)
10. Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer (New England Journal of Medicine)

Their papers

• A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization. (2018) — 1,171 citations
• PD-L1 (B7-H1) and PD-1 Pathway Blockade for Cancer Therapy: Mechanisms, Response Biomarkers and Combinations (2016) — 2,193 citations
• Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future. (2015) — 1,205 citations
• Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy (2014) — 2,243 citations
• Programmed death ligand-1 expression in non-small cell lung cancer (2013) — 753 citations
• Evidence for a role of the PD-1:PD-L1 pathway in immune resistance of HPV-associated head and neck squamous cell carcinoma (2013) — 738 citations
• Molecular mechanisms of T cell co-stimulation and co-inhibition (2013) — 2,955 citations
• Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer (2012) — 11,924 citations
• Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape (2012) — 2,143 citations
• Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates (2010) — 2,866 citations
• PD-1 regulates germinal center B cell survival and the formation and affinity of long-lived plasma cells (2010) — 708 citations
• Inhibitory B7-family molecules in the tumour microenvironment (2008) — 1,594 citations
• Immunostimulatory monoclonal antibodies for cancer therapy (2007) — 628 citations
• B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma (2006) — 761 citations
• Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity. (2005) — 1,038 citations
• Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival (2004) — 5,364 citations
• Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target. (2004) — 620 citations
• Co-inhibitory molecules of the B7–CD28 family in the control of T-cell immunity (2004) — 1,336 citations
• Blockade of B7-H1 improves myeloid dendritic cell–mediated antitumor immunity (2003) — 1,357 citations
• B7-H4, a molecule of the B7 family, negatively regulates T cell immunity. (2003) — 724 citations